Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AdaptHealth Corp (AHCO) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
AdaptHealth CorpTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs AdaptHealth Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.51 (market cap $5.07B), while AdaptHealth Corp trades at $5.77 (market cap $753.09M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 6.7× AdaptHealth Corp's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.

ACADAHCO
Market Cap
$5.07B$753.09M
Sector
HealthHealth
52-Week High
$29.41$13.38
52-Week Low
$20.06$5.22
Enterprise Value
$4.19B$2.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

AdaptHealth Corp

AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.

The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About AdaptHealth Corp

AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.

Read more on AHCO